Accentia extends option to license all antifungals for chronic sinusitis from Mayo Clinic

By Lisa Kerner

Charlotte, N.C., July 24 - Accentia Biopharmaceuticals, Inc. said an amendment to its exclusive option agreement with the Mayo Foundation for Medical Research and Education (Mayo Clinic) gives the company an additional year - until Dec. 6, 2007 - to license any and all intranasal antifungals for chronic sinusitis.

The option agreement extends beyond the anticipated New Drug Application filing date for SinuNase, an intranasal amphotericin B for refractory chronic sinusitis.

Currently, there is no drug approved by the Food and Drug Administration for the treatment of chronic sinusitis, which affects about 31 million U.S. patients.

SinuNase has received fast-track status from the FDA and is the only drug to reach phase 3 clinical trials for chronic sinusitis, officials said.

Accentia is a biopharmaceutical company develops and commercializes late-stage clinical therapeutics for respiratory disease and oncology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.